Swedish rare disease company Immedica Pharma AB announced on Monday that it has agreed to acquire Marinus Pharmaceuticals Inc (NASDAQ: MRNS) through a tender offer and subsequent merger, valuing the transaction at USD151m.

The deal offers USD0.55 per share in cash, representing a 48% premium on Marinus' closing price as of 27 December and a 97% premium on its 30-day average price. Marinus' Board has unanimously approved the transaction, which is set to close in Q1 2025.

The acquisition bolsters Immedica's rare disease portfolio by adding global rights to ZTALMY (ganaxolone), an FDA-approved treatment for seizures linked to CDKL5 deficiency disorder. ZTALMY, also approved in the EU, UK and China, provides Immedica with an immediate revenue stream and accelerates its expansion into North America.

Immedica focuses on rare disease and specialty care products, serving over 50 countries.

Marinus specializes in seizure disorder treatments, with ZTALMY as its flagship product.

MTS Health Partners advised Immedica, with legal support from Gibson, Dunn & Crutcher LLP. Barclays Capital advised Marinus, with Hogan Lovells LLP as legal counsel.